Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Krystal Biotech, Inc. (NASDAQ: KRYS)
KRYS Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
15.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
3.40%
KRYS Stock Analysis
KRYS
PE Ratio:
40.4
KRYS
PEG Ratio:
1.6
KRYS
Forward EPS Growth (12 month):
25.50%
KRYS
PS Ratio:
21.3
KRYS
PSG Ratio:
0.8
KRYS
Forward Revenue Growth (12 month):
28.10%
KRYS Articles
No data was found